Saba/Boaz Weinstein Increases GRX Stake to 2,025,826 Shares

Rhea-AI Filing Summary

The filing reports that Saba Capital Management, L.P. and Boaz Weinstein, both identified as a director and 10% owner, purchased 19,101 shares of Gabelli Healthcare & WellnessRx Trust (GRX) on 08/21/2025 at a price of $9.43 per share. After the transaction, the reporting persons are shown as beneficially owning 2,025,826 shares indirectly. The Form 4 reflects a routine insider purchase disclosed under Section 16.

Positive

• Insider purchase disclosed: 19,101 shares bought on 08/21/2025 at $9.43
• Increased indirect ownership: Beneficial holdings rise to 2,025,826 shares

Negative

• None.

Insights

Financial Analyst

TL;DR: A substantial insider-affiliated purchase of 19,101 GRX shares at $9.43 increases indirect holdings to 2,025,826 shares.

The reported purchase by Saba Capital Management and Boaz Weinstein is a direct disclosure of insider-affiliated buying activity. A 19,101-share acquisition at $9.43 is a clear signal of additional exposure by a director and 10% owner, raising their indirect stake to 2,025,826 shares. For investors, this transaction documents alignment of a significant stakeholder but does not include any commentary on strategic intent or timing beyond the trade date.

Corporate Governance Expert

TL;DR: Form 4 shows compliance with disclosure rules and increased indirect ownership by a 10% owner and director.

The filing is properly completed to report changes in beneficial ownership by persons subject to Section 16. It identifies the reporting parties, their relationship to the issuer, the transaction date, number of shares purchased, and the post-transaction indirect holding. The report contains no amendments, derivative transactions, or explanations beyond the signature acknowledgments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gabelli Healthcare & WellnessRx Trust [ GRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		P		19,101	A	$9.43	2,025,826	I	-

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Saba Capital Management, L.P.

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Weinstein Boaz

(Last) (First) (Middle)

405 LEXINGTON AVENUE

58TH FLOOR

(Street)

NEW YORK NY 10174

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

	Saba Capital Management, L.P. By: Zachary Gindes	08/25/2025
	Boaz Weinstein	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for GRX report?

The Form 4 reports that Saba Capital Management, L.P. and Boaz Weinstein purchased 19,101 shares of GRX on 08/21/2025 at $9.43 per share.

How many GRX shares do the reporting persons beneficially own after the transaction?

After the reported purchase the filing shows 2,025,826 shares beneficially owned indirectly.

What is the relationship of the reporting persons to GRX?

Both Saba Capital Management, L.P. and Boaz Weinstein are identified as a director and a 10% owner of the issuer.

When was the transaction executed according to the Form 4?

The transaction date listed on the Form 4 is 08/21/2025.

What price was paid per share in the reported transaction?

The reported purchase price was $9.43 per share.